35Pharma
4 known investors
35Pharma is a biopharmaceutical company that designs and develops ligand traps targeting the Activin x GDF signaling pathway to treat pulmonary hypertension, heart failure, and obesity. Its lead candidate, HS235, is in clinical development for cardiometabolic disease and pulmonary hypertension; the company has been acquired by GSK.
Investors · 4
Funding
SEC filings, press & company announcements- Undisclosed amountSeries CNov 2024Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does 35Pharma do?
- 35Pharma is a biopharmaceutical company that designs and develops ligand traps targeting the Activin x GDF signaling pathway to treat pulmonary hypertension, heart failure, and obesity. Its lead candidate, HS235, is in clinical development for cardiometabolic disease and pulmonary hypertension; the company has been acquired by GSK.
- Who are 35Pharma's investors?
- 35Pharma's investors include Frazier Life Sciences, venBio Partners, Janus Henderson Investors, Vivo Capital.